Bilirubin Binding Panel for Neurotoxicity Risk Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing and treating bilirubin levels in newborns are uncertain, leading to excessive treatments and risks due to reliance on total bilirubin concentration (BTotal) without considering bilirubin binding capacity, which affects the risk of bilirubin-induced neurological dysfunction (BIND).
Innovation Solution
The development of a Bilirubin Binding Panel (BBP) that includes measuring total and unbound bilirubin concentrations, along with calculating the maximum bilirubin binding capacity (BTmax) and equilibrium association constant (KA), to determine the relative risk of BIND and guide treatment decisions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods rely on total bilirubin concentration (BTotal) alone for treatment decisions, then treatment guidelines are simple to follow, but treatment accuracy is insufficient leading to excessive treatments and risks
Solution Approach 1:
The patent segments the total bilirubin measurement into two distinct components: bound bilirubin (attached to albumin) and unbound/free bilirubin (circulating independently). This segmentation is achieved through selective measurement methods that can distinguish between albumin-bound and unbound fractions. By separating these components, the patent enables more precise assessment of neurotoxicity risk, as unbound bilirubin is the fraction that can cross the blood-brain barrier and cause kernicterus, while reducing unnecessary treatments by identifying patients whose total bilirubin is elevated but bound fraction is predominant.
Solution Approach 2:
The patent introduces albumin binding capacity as an intermediary parameter that mediates between total bilirubin concentration and neurotoxicity risk. By measuring both BTotal and unbound bilirubin (BFree), the patent calculates the albumin binding capacity which serves as a mediator to determine the actual risk of bilirubin neurotoxicity. This intermediary measurement allows clinicians to interpret BTotal in the context of albumin binding function, thereby improving treatment accuracy without requiring overly complex direct neurotoxicity measurements.
2Adaptability or versatility
If treatment decisions are based on BTotal alone, then treatment protocols are easy to implement, but individualized care is insufficient
Solution Approach 1:
The patent performs preliminary assessment of albumin binding capacity and unbound bilirubin fraction before making treatment decisions. By measuring BFree and calculating albumin binding capacity in advance, the patent provides clinicians with individualized risk stratification data that guides treatment threshold selection. This preliminary action enables tailored treatment protocols where patients with high unbound fractions receive treatment at lower BTotal thresholds, while patients with predominantly bound bilirubin can tolerate higher BTotal without treatment, thus achieving individualized care while maintaining operational simplicity through pre-calculated risk parameters.
Solution Approach 2:
The patent changes the treatment decision parameters from relying solely on BTotal to incorporating BFree and albumin binding capacity measurements. By introducing these additional parameters, the patent enables individualized treatment thresholds that adapt to each patient's albumin binding status. The treatment decision framework is modified to consider the ratio of unbound to total bilirubin, allowing clinicians to adjust treatment thresholds based on the patient's specific binding characteristics, thereby achieving versatility in individualized care while providing clear operational guidelines.
3Reliability
If only BTotal is measured, then testing is simple and quick, but the risk of bilirubin-induced neurological dysfunction cannot be accurately determined
Solution Approach 1:
The patent extracts the unbound bilirubin fraction from the total bilirubin measurement by using selective detection methods that identify only the unbound portion. This extraction is achieved through techniques such as peroxidase-based assays or fluorescent probes that specifically react with unbound bilirubin, separating this critical neurotoxic fraction from the bound fraction. By taking out and independently measuring the unbound bilirubin, the patent enables reliable determination of BIND risk, as this extracted fraction directly correlates with blood-brain barrier penetration and neurological injury risk, while providing additional information about albumin binding status.
Solution Approach 2:
The patent creates a computational model that copies and simulates the complex bilirubin-albumin binding equilibrium based on measured parameters (BTotal, BFree, and binding constants). This computational copy allows clinicians to determine albumin binding capacity and predict unbound bilirubin levels at different total bilirubin concentrations without requiring direct measurement under all conditions. The model replicates the binding behavior using established equilibrium constants, enabling reliable BIND risk assessment across a range of clinical scenarios while requiring only limited laboratory measurements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a more accurate assessment of bilirubin binding, reducing unnecessary treatments and improving the determination of when to treat newborns by quantifying how well plasma binds bilirubin, thus individualizing care and reducing the uncertainties in current treatment guidelines.
Implementation Method 1
measuring total and unbound bilirubin concentrations
Implementation Method 2
The peroxidase test measures both BTotal and BFree
Implementation Method 3
quantifying how well plasma binds bilirubin comprising: determining a maximum total bilirubin concentration (BTmax) and the corresponding equilibrium association constant (KA)
Data Source
AI summary
In alternative embodiments are provided methods, devices and systems that use clinical data to determine whether bilirubin binding is normal in a newborn infant with hyperbilirubinemia in order to detect in vivo neurologically toxic levels of bilirubin and to determine whether treatment is needed to prevent a bilirubin-induced neurological injury (e.g. encephalopathy). In alternative embodiments, also provided are devices and systems comprising automated micro-fluid handling technologies such as zone fluidics systems to obtain a bilirubin binding panel. In alternative embodiments, also provided are methods for using the bilirubin binding panel to determine if treatments are needed to ameliorate, reverse, or prevent a bilirubin-induced neurological injury (e.g. encephalopathy) in an individual in need thereof such as a newborn with hyperbilirubinemia (jaundice), and for commencing the treatment, if needed.